Metastatic Prostate Cancer (mPC)
Conditions
Brief summary
Preclinical studies have confirmed that \[68Ga\]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables \[68Ga\]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential killing two birds with one stone imaging agent. At this stage, the clinical study of \[68Ga\]Ga-P17-079 in the diagnosis and treatment of metastatic prostate cancer as a self-made preparation is planned to be carried out in our hospital to further verify its clinical application value.
Interventions
DIAGNOSTIC_TESTP17-079, P16-093, or P15-041 PET/CT
P17-079, P16-093, or P15-041 PET/CT
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male aged 18-85 years, expected survival ≥12 weeks. * Patients who have not undergone chemoradiotherapy, feasible surgery or biopsy to obtain a pathological diagnosis or are highly suspected of malignancy according to clinical diagnostic criteria. * At least one measurable target lesion was present according to RECIST1.1 criteria. * Obtain written informed consent and be able to follow up
Exclusion criteria
* Severe abnormal liver and kidney function * Fertile subjects will need to use effective contraception during the study * Unable to lie flat for half an hour * Refused to join this clinical investigator * Suffering from claustrophobia or other mental illness * Other conditions deemed unsuitable for participation in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUV | 0-180 min post-injection | measured by PET/CT |
Countries
China
Outcome results
None listed